首页> 美国卫生研究院文献>BMC Cancer >Outcomes based on plasma biomarkers in METEOR a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

【2h】

Outcomes based on plasma biomarkers in METEOR a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

机译：基于血浆生物标志物的结果在晚期肾细胞癌中的Cabozantib vs everolimus的随机相3试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version contains supplementary material available at 10.1186/s12885-021-08630-w.

机译：在线版本包含10.1186 / S12885-021-08630-W提供的补充材料。

著录项

期刊名称 BMC Cancer
作者
Thomas Powles; Toni K. Choueiri; Robert J. Motzer; Eric Jonasch; Sumanta Pal; Nizar M. Tannir; Sabina Signoretti; Rajesh Kaldate; Christian Scheffold; Evelyn Wang; Dana T. Aftab; Bernard Escudier; Daniel J. George;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：Cabozantib;everolimus;肾细胞癌;生物标志物;流星;

相似文献

外文文献
中文文献
专利

1. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma [J] . Powles Thomas, Choueiri Toni K., Motzer Robert J., BMC Cancer . 2021,第1期

机译：基于流星中血浆生物标志物的结果，在晚期肾细胞癌中的Cabozantib vs everolimus的随机相3试验
2. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020,第期

机译：基于年龄在高级肾细胞癌患者的Cabozantinib患者的III阶段流星试验的成果
3. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma [J] . Thomas Powles, Robert J. Motzer, Bernard Escudier, British Journal of Cancer . 2018,第6期

机译：卡博替尼与依维莫司在晚期肾细胞癌的3期METEOR试验中基于先前治疗的结果
4. Designing Phase III Trials in Metastatic Renal Cell Carcinoma: What Are the New Standards? [C] . Ana M. Molina Genitourinary Cancers Symposium . 2012

机译：在转移性肾细胞癌中设计III期试验：新标准是什么？
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma [O] . Thomas Powles, Robert J. Motzer, Bernard Escudier, 2018

机译：卡波替尼与依维莫司在晚期肾细胞癌的3期METEOR试验中基于先前治疗的结果
7. Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma [O] . Nizar M. Tannir, Thomas Powles, Bernard Escudier, 2020

机译：流星肾切除术地位的临床结果，随机相3试验Cabozantib对患者肾细胞癌的患者

Outcomes based on plasma biomarkers in METEOR a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅